Physician profile
Holly D Walker
NPI 1295763316
$1,491.40
in general payments reported to CMS, 2019-2025
22 companies · $780 in 2025
The $780 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $215 · 2023: $202 · 2024: $295 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $414.11 | 2022-2025 | Wakix |
| Abbvie INC. | $132.96 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $116.44 | 2022-2025 | |
| Axsome Therapeutics, INC. | $114.10 | 2023-2025 | Sunosi |
| Lilly USA, LLC | $103.71 | 2025 | Kisunla, Amyvid |
| Glaxosmithkline, LLC. | $86.41 | 2023-2025 | Arexvy, Shingrix |
| Avadel Cns Pharmaceuticals, LLC | $58.05 | 2025 | Lumryz |
| Grifols USA, LLC | $50.22 | 2025 | Gamunex-C |
| Sk Life Science, INC. | $49.93 | 2024-2025 | |
| Neurelis, INC. | $48.82 | 2025 | Valtoco |
| Argenx US, INC. | $48.11 | 2024-2025 | Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $32.09 | 2025 | Ultomiris |
| Kyowa Kirin, INC. | $31.71 | 2024 | Nourianz |
| Boston Scientific Corporation | $30.62 | 2024 | |
| Janssen Pharmaceuticals, INC | $28.56 | 2022-2023 | Spravato |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $27.30 | 2025 | |
| Pfizer INC. | $25.84 | 2024 | |
| Lundbeck LLC | $23.15 | 2025 | Vyepti |
| Acadia Pharmaceuticals INC | $22.39 | 2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $19.37 | 2024 | Ingrezza |
| Janssen Biotech, INC. | $14.47 | 2025 | |
| Merck Sharp & Dohme LLC | $13.04 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.